Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan.
10.1186/s12199-021-01035-y
- Author:
Emma Nakagawa HOFFMAN
1
;
Haruna KAWACHI
1
;
Atsushi HIRAYAMA
1
;
Jingwen ZHANG
1
;
Ayumi MURAYAMA
1
;
Jun MASUI
1
;
Satomi FUJITA
1
;
Yasushi MORI
1
;
Takanori HIRAYAMA
1
;
Toshitake OHARA
1
;
Rumiko ASADA
1
;
Hiroyasu ISO
2
Author Information
1. Osaka Prefectural Government, Department of Public Health and Medical Affairs, 1-2 Otemae, Chuo-ku, Osaka, 540-8570, Japan.
2. Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan. iso@pbhel.med.osaka-u.ac.jp.
- Publication Type:Observational Study
- Keywords:
COVID-19;
Comorbidity;
Longitudinal studies;
Virus shedding
- MeSH:
Adult;
COVID-19;
Humans;
Japan/epidemiology*;
RNA, Viral;
SARS-CoV-2;
Virus Shedding
- From:Environmental Health and Preventive Medicine
2021;26(1):115-115
- CountryJapan
- Language:English
-
Abstract:
BACKGROUND:We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities.
METHODS:Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset.
RESULTS:The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11-2.82]) for one, (OR, 2.47 [95% CI, 1.32-4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity.
CONCLUSION:The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity.
